脂蛋白相关磷脂酶A2与动脉粥样硬化的关系

被引：25

作者：

刘建辉

张春妮

机构：

[1] 中国人民解放军南京军区南京总医院检验科全军检验医学研究所

来源：

中国动脉硬化杂志 | 2008年 / 07期

关键词：

病理学与病理生理学; 脂蛋白相关磷脂酶A2; 脂蛋白; 炎症; 动脉粥样硬化; 抑制剂;

D O I：

暂无

中图分类号：

R543 [血管疾病];

学科分类号：

100201 [内科学];

摘要：

脂蛋白相关磷脂酶A2是一种炎性细胞分泌的能促使氧化磷脂水解的磷脂酶,血液循环中该酶的活性与年龄性别血脂水平及基因多态性等多种因素有关。脂蛋白相关磷脂酶A2主要以与脂蛋白结合的形式存在,它既能通过水解血小板活化因子、氧化磷脂等炎症介质达到抗动脉硬化的效果,又能通过水解氧化低密度脂蛋白分子中的氧化磷脂,使其产生促炎症物质溶血卵磷脂和氧化型游离脂肪酸而起到促动脉粥样硬化作用,因此与动脉粥样硬化的发生发展密切相关。脂蛋白相关磷脂酶A2的特异性抑制剂已被证实具有抗动脉硬化作用,脂蛋白相关磷脂酶A2正被作为动脉粥样硬化治疗的一个新靶点而受到广泛关注。

引用

页码：569 / 571

页数：3

共 13 条

[1]

老年人血浆脂蛋白相关磷脂酶A2活性与其基因型、性别和年龄的关系 [J].

张绍艳 ;

王滨有 .

中国动脉硬化杂志, 2007, (11) :854-856

[2]

Lipoprotein-associated phospholipase A<Subscript>2</Subscript> for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach.[J].M. Möckel;Reinhold Müller;Jörn O. Vollert;Christian Müller;Oilver Danne;Ragnar Gareis;Thomas Störk;Rainer Dietz;Wolfgang Koenig.Clinical Research in Cardiology.2007, 9

[3]

Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target [J].

Macphee, CH ;

Nelson, J ;

Zalewski, A .

CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (02) :154-161

[4]

Potent inhibitors of lipoprotein-associated phospholipase A2:: Benzaldehyde O-heterocycle-4-carbonyloxime [J].

Jeong, Hyung Jae ;

Park, Yong-Dae ;

Park, Ho-Yong ;

Jeong, Il Yun ;

Jeong, Tae-Sook ;

Lee, Woo Song .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (21) :5576-5579

[5]

Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus [J].

Wootton, P. T. E. ;

Stephens, J. W. ;

Hurel, S. J. ;

Durand, H. ;

Cooper, J. ;

Ninio, E. ;

Humphries, S. E. ;

Talmud, P. J. .

ATHEROSCLEROSIS, 2006, 189 (01) :149-156

[6]

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke - The Rotterdam Study [J].

Oei, HHS ;

van der Meer, IM ;

Hofman, A ;

Koudstaal, PJ ;

Stijnen, T ;

Breteler, MMB ;

Witteman, JCM .

CIRCULATION, 2005, 111 (05) :570-575

[7]

The identification of clinical candidate SB-480848:: A potent inhibitor of lipoprotein-associated phospholipase A2 [J].

Blackie, JA ;

Bloomer, JC ;

Brown, MJB ;

Cheng, HY ;

Hammond, B ;

Hickey, DMB ;

Ife, RJ ;

Leach, CA ;

Lewis, VA ;

Macphee, CH ;

Milliner, KJ ;

Moores, KE ;

Pinto, IL ;

Smith, SA ;

Stansfield, IG ;

Stanway, SJ ;

Taylor, MA ;

Theobald, CJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (06) :1067-1070

[8]

Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe [J].

Abuzeid, AM ;

Hawe, E ;

Humphries, SE ;

Talmud, PJ .

ATHEROSCLEROSIS, 2003, 168 (02) :283-288

[9]

Evidence for a Role of Phospholipid Oxidation Products in Atherogenesis.[J].Judith A. Berliner;Ganesamoorthy Subbanagounder;Norbert Leitinger;Andrew D. Watson;Devendra Vora.Trends in Cardiovascular Medicine.2001, 3

[10]

The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2 [J].